<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150850</url>
  </required_header>
  <id_info>
    <org_study_id>A00-M23-12A</org_study_id>
    <nct_id>NCT02150850</nct_id>
  </id_info>
  <brief_title>Quebec Registry for Atypical Femur Fractures</brief_title>
  <official_title>Quebec Registry for Atypical Femur Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fonds de la Recherche en Santé du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bisphosphonates are recommended as first-line agents to reduce fracture risk in patients with
      osteoporosis and have in general an excellent safety profile. However, recent reports have
      noted that prolonged use of bisphosphonates may be associated with rare but serious adverse
      effects, namely atypical femur fractures (AFF), an atraumatic subset of subtrochanteric and
      diaphyseal fractures.

      The overarching aim of this project is to contribute to the characterization of clinical,
      biomechanical, radiological and genetic predictors of AFF, associated or not with
      bisphosphonate and-or denosumab therapy. AFF arise on the lateral (external) aspect of the
      subtrochanteric and diaphyseal regions of the femur, regions subjected to high mechanical
      loads. Because of this unique distribution, the investigators hypothesis is that patients
      with AFF demonstrate specific geometrical variations of their femur whereby baseline tensile
      forces applied to the lateral cortex are higher and might favour the appearance of these rare
      stress fractures. Measurements to investigate these geometric variations with be calculated
      from 3D images reconstructed using scans procured using the EOS® low irradiation 2D-3D X-Ray
      scanner.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Predictors associated with AFFs</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured as the frequency of possible risk factors including demographic and clinical characteristics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in lower limb geometric parameters between cases and controls</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured from 3D images reconstructed using scans procured using the EOS® low irradiation 2D-3D X-Ray scanner.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in functional impairment</measure>
    <time_frame>6- 12- 24- 36- months post fracture</time_frame>
    <description>Measured using the Lower Extremity Functional Scale (LEFS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in global function status</measure>
    <time_frame>6- 12- 24- 36- months post fracture</time_frame>
    <description>Measured using The Reintegration to Normal Living Index (RNLI).</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atypical Femur Fracture</condition>
  <arm_group>
    <arm_group_label>Registry</arm_group_label>
    <description>Patients who have who have sustained an AFF that consent to participating in the registry only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients who have sustained an AFF that consent to participating in the registry and undergoing EOS® imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>For each case we will identify one age- (± 5 years), sex-, height- (± 6 cm) and cumulative bisphosphonate or denosumab exposure ( ±2 years) matched control who has not sustained an AFF to undergo EOS® imaging.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      AFF patients only will be asked to deposit 2 ml of saliva into a collection tube using a
      standardized protocol. Individuals unable to produce 2ml of saliva will be asked to perform
      at least two buccal swabs.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have sustained an AFF.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 45 years and older

          -  men and women from Quebec who sustain (or have sustained) an AFF (complete or
             incomplete), as defined by the American Society of Bone and mineral Research (ASBMR)
             International Task Force on AFFs (Shane E et al J Bone Miner Res 2014;29:1-24)

        Exclusion Criteria:

          -  inability to consent

          -  disorders of bone metabolism other than osteoporosis

          -  active cancer

          -  life expectancy less than 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Morin, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Wall, MSc.</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>45742</phone_ext>
    <email>michelle.wall@mail.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Dr. Suzanne Morin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Femoral Fractures</keyword>
  <keyword>Subtrochanteric Fractures</keyword>
  <keyword>Osteoporotic Fractures</keyword>
  <keyword>Fractures, Spontaneous</keyword>
  <keyword>Stress Fractures</keyword>
  <keyword>Bone Fractures</keyword>
  <keyword>Hip Fractures</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

